WINNIPEG, MANITOBA--(Marketwire - January 15, 2008) - Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce that it has received a $405,000 contribution from the National Research Council Industrial Research Assistance Program (NRC-IRAP). The contribution will be applied to the development of the Company's novel antibiofilm topical wound gel containing its patented DispersinB™ technology. DispersinB™ wound gel is being developed to treat chronic wound infections.
